GLP-1 receptor agonists also reduce glucagon secretion
Now, two new studies presented at the European Congress on Obesity, have shown that not only can semaglutides aid weight loss, they may also help reduce the risk of heart attack, stroke and other dangerous heart events in people without type 2 diabetes
This assessment was carried out using the Dummett and Gupta Oral Pigmentation Indexs predetermined score criteria[9] [Table 1]
When the benefit outweighs the side effect, and when it might not For most patients, the metabolic benefits of GLP-1 therapy, including improved cardiovascular risk factors, better insulin sensitivity, reduced visceral fat, and meaningful weight loss, far outweigh a temporary or modest change in libido